Rapport Therapeutics (RAPP) Capital Expenditures (2023 - 2026)
Rapport Therapeutics (RAPP) reported Capital Expenditures of $86000.0 for Q1 2026, down 70.45% year-over-year from $291000.0 in Q1 2025, and down 49.11% quarter-over-quarter from $169000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Capital Expenditures (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Capital Expenditures data on file, last reported at $86000.0 in Q1 2026.
- Capital Expenditures for Q1 2026 came in at $86000.0, down 70.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $411000.0 (down 74.69% YoY), and the FY2025 annual result was $616000.0, down 74.39% from the prior year.
- Capital Expenditures fell to $86000.0 in Q1 2026 per RAPP's latest filing, from $169000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.4 million in Q4 2023 and troughed at $22000.0 in Q2 2025.
- A 4-year average of $417818.2 and a median of $169000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures surged 169.23% in 2024, then slumped 97.72% in 2025.
- A 4-year view of Capital Expenditures shows it stood at $1.4 million in 2023, then tumbled by 84.27% to $226000.0 in 2024, then decreased by 25.22% to $169000.0 in 2025, then slumped by 49.11% to $86000.0 in 2026.
- Business Quant data shows RAPP's Capital Expenditures at $86000.0 in Q1 2026, $169000.0 in Q4 2025, and $134000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -63,220.27 |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86,000.00 |
| Mar 31, 2026 | 86,000.00 |
| Dec 31, 2025 | 169,000.00 |
| Dec 31, 2025 | 169,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 22,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | 967,000.00 |
| Jun 30, 2024 | 967,000.00 |
| Mar 31, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Dec 31, 2023 | 1.44 Mn |